Storia in 8 fonti

Revolution Medicines starts shipping experimental pancreatic cancer drug

CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

Raccontata da

pharmaceutical-technology.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.com1 mesi fa

Practice-changing results reported for Revolution Medicines pancreatic cancer drug

Revolution Medicines' daraxonrasib, a targeted oral therapy for pancreatic cancer, roughly doubled patient survival versus standard chemotherapy in a Phase trial presented at ASCO 2026 and published simultaneously in the New England Journal of Medicine. For biotech and oncology investors, this is the first meaningful efficacy signal in a notoriously treatment-resistant indication, likely to accelerate M&A interest and pipeline repositioning toward RAS-targeted agents.

Leggi questa versione → originale

Revolution Medicines starts shipping experimental pancreatic cancer drug

Confronto fonti

Practice-changing results reported for Revolution Medicines pancreatic cancer drug

Timeline cronologica

Pancreatic cancer is deadly and difficult to treat. A new pill could change that